FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

PE-22-28

Proenkephalin Fragment

Fat Loss & Body Composition

PE-22-28 is a synthetic heptapeptide derived from the active region of Spadin, a naturally occurring peptide that functions as a specific antagonist of the TREK-1 potassium channel (KCNK2), a validated target for antidepressant therapy. By blocking TREK-1 channels, it produces rapid-onset antidepressant effects similar to those observed with SSRIs but within days rather than weeks, while also promoting hippocampal neurogenesis. Its primary research applications focus on treatment-resistant depression, cognitive enhancement, and neuroplasticity modulation.

작용 메커니즘

Fragment of proenkephalin that modulates opioid receptor signaling in adipose tissue. Promotes brown adipose tissue thermogenesis and white adipose tissue browning. Enhances uncoupling protein 1 (UCP1) expression, increasing non-shivering thermogenesis and energy expenditure.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols use 500mcg-1mg subcutaneously daily. Limited human data. Animal studies used varying doses. Often discussed alongside other fat-loss peptides. Cycles of 4-8 weeks.

연구 노트

Clinical Research Status

PE-22-28 is in preclinical research stages, building on the published work demonstrating Spadin and its analogs as a novel class of antidepressants acting through TREK-1 channel blockade. The parent compound Spadin was characterized by researchers at CNRS and University of Nice, with PE-22-28 representing an optimized shorter fragment with improved stability and blood-brain barrier penetration. No human clinical trials have been initiated specifically for PE-22-28, though the TREK-1 target has been validated in multiple preclinical depression models.

Key Published Findings

Research demonstrates that PE-22-28 produces antidepressant-like effects in mouse models (forced swim test, tail suspension test) within 4 days of administration, compared to 2-3 weeks required for SSRI onset of action. TREK-1 knockout mice display a depression-resistant phenotype identical to the effects produced by pharmacological blockade with PE-22-28 and related analogs. The compound has been shown to stimulate hippocampal neurogenesis and increase BDNF expression, providing a mechanistic basis for both its antidepressant and potential cognitive-enhancing effects through neuroplasticity promotion.

Safety Profile

Preclinical studies suggest good tolerability with no observed toxicity at effective antidepressant doses in animal models. TREK-1 channels are expressed in multiple tissues beyond the brain (heart, smooth muscle, adrenal gland), raising theoretical concerns about peripheral effects that have not been fully characterized. As a research compound without human trial data, the safety profile in humans including appropriate dosing, potential for dependence, and long-term effects on channel regulation remains undetermined.

Drug Interactions & Contraindications

Theoretical interactions exist with existing antidepressant medications (SSRIs, SNRIs, MAOIs) as combining multiple mechanisms affecting serotonergic and neuroplasticity pathways could produce unpredictable effects. TREK-1 channels play roles in neuroprotection during ischemia, so concurrent use with compounds affecting cerebrovascular function warrants caution. Individuals with cardiac arrhythmias should exercise caution given the expression of TREK-1 channels in cardiac tissue, though the degree to which PE-22-28 affects peripheral channels at therapeutic brain concentrations is unknown.

Comparison to Related Compounds

Spadin (the parent peptide) is a 17-amino-acid peptide with the same mechanism but poorer stability and shorter half-life compared to the optimized PE-22-28 fragment. Unlike SSRIs which require 2-4 weeks for therapeutic onset and carry sexual dysfunction and emotional blunting side effects, TREK-1 antagonism offers rapid-onset antidepressant action through a fundamentally different mechanism. Ketamine and its analogs also provide rapid antidepressant effects but through NMDA receptor antagonism with dissociative side effects and abuse potential that are not associated with TREK-1 blockade.

Community Observations

Users exploring PE-22-28 typically report noticeable mood improvements and cognitive clarity within 3-7 days of intranasal or subcutaneous administration at doses extrapolated from preclinical research (typically in the low microgram range). Reports suggest it produces a calm, clear-headed improvement in mood without the emotional numbing or sexual side effects commonly associated with SSRI medications. The research community notes that PE-22-28 represents one of the few peptide-based approaches to depression with a clearly validated molecular target, though sourcing verified high-purity material remains challenging due to its relative obscurity compared to mainstream research peptides.

반감기

~1-2 hours

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C up to 12 months.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

Proenkephalin Fragment

자주 묻는 질문

PE-22-28란 무엇인가요?

PE-22-28 is a synthetic heptapeptide derived from the active region of Spadin, a naturally occurring peptide that functions as a specific antagonist of the TREK-1 potassium channel (KCNK2), a validated target for antidepressant therapy. By blocking TREK-1 channels, it produces rapid-onset antidepressant effects similar to those observed with SSRIs but within days rather than weeks, while also promoting hippocampal neurogenesis. Its primary research applications focus on treatment-resistant depression, cognitive enhancement, and neuroplasticity modulation.

PE-22-28는 어떻게 작용하나요?

Fragment of proenkephalin that modulates opioid receptor signaling in adipose tissue. Promotes brown adipose tissue thermogenesis and white adipose tissue browning. Enhances uncoupling protein 1 (UCP1) expression, increasing non-shivering thermogenesis and energy expenditure.

PE-22-28의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

PE-22-28의 반감기는 얼마인가요?

~1-2 hours

PE-22-28의 다른 이름은 무엇인가요?

Proenkephalin Fragment

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기